Autopsy report · NCT03416816

A Study of DSP-0337 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile

“Alternate development strategy”

The sponsor’s own words in the registry.

Life of this trial

• Registered 4 months before it started.
• Ran for about 2 years 1 month before it stopped.
• 23 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Sumitomo Pharma America, Inc.

Sponsor type

Industry

Conditions

Neoplasms

Interventions

DSP-0337

Participants

23

Sites

4

Countries

United States

Trials that died the same way

• Study of SIM0501 Alone and in Combination in Patients With Advanced Solid Tumors
  “Company development strategy change” (76% match in meaning)
• A Clinical Investigation to Assess the Effectiveness of Benzocaine Condoms in Healthy Adult Men
  “Change of the product development strategy” (72% match in meaning)
• Clinical Trial of TJ271 Injection Combined With Pembrolizumab in the Treatment of Advanced Solid Tumors
  “Company Development strategy adjustment” (71% match in meaning)
• A Study of OVV-01 Injection in Combination With IBR900 Cell Injection in Patients With Advanced Malignant Tumors
  “Research and development strategy adjustment” (71% match in meaning)
• Study of NIB101 in Participants With Advanced Solid Tumors
  “due to the reconsideration of development strategy” (71% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.